SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the appointment of Susan Lundeen as Chief People Officer effective May 2, 2022. In this newly created role, Susan will oversee Allogene’s Human Resources efforts as the Company continues to advance a rapidly growing AlloCAR T pipeline.
Read more at globenewswire.comAllogene Therapeutics Appoints Susan Lundeen as Chief People Officer
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.